-Mr. Nick Photiades is stepping down from the Board-
BELLEVILLE, ON, Dec. 6, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based,
technology-driven Canadian biopharmaceutical company, today announced
that one of its Directors - Mr. Nick Photiades - is stepping down from
the Board of Directors.
Mr. Photiades had been the Senior Director, Life Sciences, Venture
Capital Division with the Business Development Bank of Canada until his
retirement in 2008, after which he became a management and strategic
planning consultant. He joined the Bioniche Life Sciences Inc. Board of
Directors in September, 2009.
"The Board of Directors and management of the Company wish to recognize
and thank Mr. Photiades for his three years of contribution to the
Company," said Mr. James Rae, Board Chairman, Bioniche Life Sciences
Inc. "Mr. Photiades has been a thoughtful and articulate Director, who
provided expertise in audit, legal, financing, deal-making and
strategic planning. We wish him all the best in his future endeavours."
It has been decided that the Director position vacated by Mr. Photiades
will not be filled at this time.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097